Significance of mycophenolate mofetil treatment in patients with HCV reinfection after liver transplantation: impact on clinical course and histologic damage.
Bahra
M
M
Department of Surgery, Charité Campus Virchow-Klinikum, Humboldt-University, Berlin, Germany. marcus.bahra@charite.de
Neumann
U P
UP
Harren
M
M
Jacob
D
D
Langrehr
J M
JM
Berg
T
T
Neuhaus
R
R
Neuhaus
P
P
D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000188:drug therapy*; D006526:Hepatitis C / Q000517:prevention & control / Q000601:surgery*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D012008:Recurrence; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects; D019562:Viral Load
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D009173:Mycophenolic Acid; D016559:Tacrolimus